Viridian Therapeutics Stock Rallies on Positive VRDN-008 Trial Results, Eyes 8-Week Dosing

Viridian Therapeutics Inc. (NASDAQ:VRDN) reported positive Phase 1 clinical trial results for VRDN-008, highlighting its pharmacokinetic and pharmacodynamic profile as a potential best-in-class subcutaneous treatment for autoimmune and rare diseases.

The biotechnology company confirmed the investigational therapy sustained IgG antibody reduction through eight weeks, supporting a transformative dosing schedule of once every eight weeks for future patients.

• Viridian Therapeutics stock is showing exceptional strength. What’s behind VRDN gains?

Phase 1 Trial Highlights Extended Half-Life and IgG Suppression

The Phase 1 clinical study evaluated subcutaneous VRDN-008 in healthy volunteers who received two subcutaneous doses, one at trial initiation and a second dose at week four.

VRDN-008, a bifunctional FcRn inhibitor licensed from Paragon Therapeutics, integrates an Fc fragment with an albumin-binding domain to prolong antibody suppression.

Clinical findings showed VRDN-008 achieved an extended half-life of 15 to 18 days, lasting up to six times longer than first-generation Fc fragments.

The candidate produced deep and prolonged IgG suppression, achieving a 74% IgG reduction at peak levels across the eight-week post-dosing period.

VRDN-008 also demonstrated a favorable safety profile that spared albumin and LDL cholesterol, with healthy volunteers reporting no serious adverse events or dose-limiting toxicities during the study.

Wearable On-Body Device Enables At-Home Administration

Viridian plans to administer subcutaneous VRDN-008 using the Enable enFuse wearable delivery device developed by Enable Injections.

This hands-free, on-body injector operates with a single button press, representing the next generation of drug delivery to simplify at-home self-administration.

Viridian secured exclusive global rights to enFuse for FcRn-targeted therapies in January 2023.

Registrational Study Targets Mid-2027 Launch In MG

Encouraged by the Phase 1 outcomes, Viridian plans to advance VRDN-008 rapidly into pivotal development to establish a direct path toward a Biologics License Application.

Pending feedback from regulatory authorities, the company aims to initiate at least one registrational trial in mid-2027, starting with myasthenia gravis.

The multi-arm registrational trial will deliver VRDN-008 through the enFuse system and evaluate four-week and eight-week dosing regimens against placebo.

Viridian also plans to expand VRDN-008 development into multiple autoantibody-mediated autoimmune diseases beyond myasthenia gravis.

VRDN Price Action: Viridian Therapeutics shares were up 4.69% at $29.83 at the time of publication on Monday, according to Benzinga Pro data.

Image via Shutterstock